Coherus Oncology Inc (CHRS) USD0.0001

Sell:$0.78Buy:$0.84$0.03 (3.74%)

NASDAQ:1.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.78
Buy:$0.84
Change:$0.03 (3.74%)
Market closed | Prices delayed by at least 15 minutes
Sell:$0.78
Buy:$0.84
Change:$0.03 (3.74%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Key people

Dennis M. Lanfear
Chairman of the Board, President, Chief Executive Officer
Bryan Mcmichael
Chief Financial Officer
Theresa M. Lavallee
Chief Development Officer
Mats L. Wahlstrom
Lead Independent Director
Georgia L. Erbez
Independent Director
Rita A. Karachun
Independent Director
Lee Nisley Newcomer
Independent Director
Charles W. Newton
Independent Director
Click to see more

Key facts

  • EPIC
    CHRS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US19249H1032
  • Market cap
    $92.40m
  • Employees
    221
  • Shares in issue
    115.93m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.